Pfizer announced third-quarter results: adjusted earnings per share forecast for the full year 2026 was raised from $2.80 to $3.00 to $2.95-3.05, and the market forecast was $2.96; full-year revenue guidance was raised from $605-62.5 billion to $62-64 billion, and the market forecast was $62.26 billion. The company's third-quarter adjusted earnings per share were $0.87, higher than expectations of $0.73; revenue of $16.58 billion was higher than expected of $15.87 billion. Pfizer said that the third-quarter results were due to steady global business and operational controls in place. The increase in full-year guidance reflects the company's confidence in current operating performance and business prospects.

Pfizer announced third-quarter results: adjusted earnings per share forecast for the full year 2026 was raised from $2.80 to $3.00 to $2.95-3.05, and the market forecast was $2.96; full-year revenue guidance was raised from $605-62.5 billion to $62-64 billion, and the market forecast was $62.26 billion. The company's third-quarter adjusted earnings per share were $0.87, higher than expectations of $0.73; revenue of $16.58 billion was higher than expected of $15.87 billion. Pfizer said that the third-quarter results were due to steady global business and operational controls in place. The increase in full-year guidance reflects the company's confidence in current operating performance and business prospects.